Bill
Bill > A5633
summary
Introduced
06/20/2023
06/20/2023
In Committee
06/20/2023
06/20/2023
Crossed Over
Passed
Dead
01/08/2024
01/08/2024
Introduced Session
2022-2023 Regular Session
Bill Summary
This bill requires Medicaid coverage for remote stress tests for pregnant women. Specifically, the bill provides that coverage under the Medicaid Program include benefits for expenses incurred in conducting, non-stress tests for pregnant women with high risk pregnancies, which have been approved by the United States Food and Drug Administration for at-home use to monitor fetal and maternal heart rate and uterine activity, provided that there is federal financial participation available. It is the sponsor's belief that women with high risk pregnancies are often prescribed contraction stress tests twice per week during the third trimester, but only 40 percent of such women undergo the testing. Failure to undergo prescribed contraction stress tests can worsen existing health issues and contribute to maternal mortality. According to the American College of Obstetricians and Gynecologists, the contraction stress test may be the primary means of fetal surveillance for many women with high-risk pregnancies. Undergoing such testing twice per week is impossible for many pregnant women. However, technology exists, which has been approved by the United States Food and Drug Administration, to allow for at-home, contraction stress tests, consisting of 20 to 40 minute sessions to monitor fetal heart rate, fetal movement, and uterine contractions, under the oversight of trained clinicians.
AI Summary
This bill requires Medicaid coverage for remote stress tests for pregnant women with high-risk pregnancies. Specifically, it provides that Medicaid coverage include benefits for expenses incurred in conducting non-stress tests, which have been approved by the FDA for at-home use to monitor fetal and maternal health, provided there is federal financial participation available. The bill aims to address the issue that many high-risk pregnant women are prescribed these tests twice a week during the third trimester, but only 40% undergo the testing due to the difficulty of traveling to a clinic. The remote testing technology approved by the FDA can allow these women to conduct the tests at home, under the oversight of trained clinicians, to better monitor their health and that of their babies.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Introduced, Referred to Assembly Human Services Committee (on 06/20/2023)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2022/A5633 |
| BillText | https://pub.njleg.gov/Bills/2022/A6000/5633_I1.HTM |
Loading...